<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377880</url>
  </required_header>
  <id_info>
    <org_study_id>2019_18R</org_study_id>
    <secondary_id>2020-A00027-32</secondary_id>
    <nct_id>NCT04377880</nct_id>
  </id_info>
  <brief_title>Development of Cellular Models for Osteoblast Response Study to Adipocytic Secretions in an Osteoporosis Context.</brief_title>
  <acronym>ROSA</acronym>
  <official_title>Development of Cellular Models for Osteoblast Response Study to Adipocytic Secretions in an Osteoporosis Context.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ULCO : Université du Littoral Côte d'Opale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent studies suggest that secretions from medullary adipocytes are involved in the
      mechanisms of bone loss in osteoporosis (OP) through their actions on neighbouring
      osteoforming cells, the osteoblasts. The objective of the research is the development of new
      cellular models representing the aging skeleton to confirm this hypothesis. To this end,
      osteoblasts will be isolated from human bone fragments coming from femoral heads discarded
      during total hip replacement surgery. The osteoblastic response to secreted factors released
      from medullary adipocytes of commercial origin will be analysed using conditioned media
      incubations. This phenotypic response will be quantified for each subject through the
      analysis of gene expression levels. Inter-subject phenotype variations will be related to
      bone density and microarchitecture data obtained by X-ray microtomography. This will assess
      the existence of a correlation between the osteoblast response to adipocyte secretions and
      the degree of osteoporosis of the subject from whom the cells are derived.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the level of gene expression of adipocyte markers such as PPARG and leptin</measure>
    <time_frame>Baseline</time_frame>
    <description>The effect of adipocyte secretion products on osteoblasts will be evaluated by incubating osteoblasts from human bone biopsies with commercially available adipocyte conditioned cell media. Phenotypic changes in osteoblastic cells will then be evaluated by analyzing their gene expression profile and comparing them with those of osteoblasts incubated in unconditioned media. The selected criteria for judging osteoblast alteration will be the measurement of the level of gene expression of adipocyte markers such as PPARG and leptin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-subject phenotype variations by X-ray microtomography</measure>
    <time_frame>Baseline</time_frame>
    <description>Inter-subject phenotype variations will be related to quantitative bone microarchitecture data determined by X-ray microtomography.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Osteoporosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone fragments; RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a surgical indication for a prosthetic hip joint at the Boulogne-sur-Mer
        hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subject

          -  Surgical indication for hip prosthesis implantation

          -  Affiliation to a social insurance regime

        Exclusion Criteria:

          -  Rejection of participation

          -  Diagnosed bone diseases other than osteoarthritis or osteoporosis

          -  Cancer

          -  Pregnant Women

          -  Subject under guardianship or trusteeship

          -  Subject unable to understand the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric FODZO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric FODZO, MD</last_name>
    <phone>321998835</phone>
    <phone_ext>+33</phone_ext>
    <email>e.fodzo@ch-boulogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eric FODZO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteoblast</keyword>
  <keyword>Adipocyte</keyword>
  <keyword>Cellular models</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

